Liminal BioSciences Provides R&D Update

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead...

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,Canada ,Fairhaven ,Newfoundland ,Bruce Pritchard ,Liminal Biosciences Inc ,Fairhaven Pharmaceuticals Inc ,World Health Organisation ,Agonist Development Program ,Nasdaq ,Antagonist Development Program ,Market Watch Research ,Chief Executive Officer ,Watch Research ,Future Market Insights ,Gary Bridger ,Interim Chief Scientific Officer ,Study Results ,